Hexarelin

Most Common Uses

Hexarelin is primarily used in research settings to explore its effects on growth hormone secretion. Researchers administer it to study its potential in enhancing muscle growth, improving recovery from injuries, and supporting tissue repair due to its ability to stimulate the release of growth hormone from the pituitary gland. In experimental contexts, Hexarelin is investigated for its role in addressing growth hormone deficiencies, particularly in models of hormonal imbalances.

Its use extends to exploring benefits in bone density improvement and cardiac function, as it may enhance cardiac performance in certain preclinical studies. Typically administered via subcutaneous or intramuscular injection, Hexarelin remains a research peptide, with clinical applications limited by regulatory restrictions in many regions. Ongoing studies continue to evaluate its therapeutic potential in various physiological systems.

Mechanism of Action

Hexarelin functions as a potent growth hormone secretagogue by targeting the ghrelin receptor (GHS-R1a) in the pituitary gland and hypothalamus. Upon binding to these receptors, it stimulates the release of growth hormone in a dose-dependent manner, leading to increased circulating levels of insulin-like growth factor-1 (IGF-1), which supports tissue growth and repair. Hexarelin also enhances prolactin and cortisol secretion to a lesser extent, influencing metabolic and stress responses.

Its activation of ghrelin receptors in cardiac tissue may improve cardiac function by enhancing contractility and reducing apoptosis in heart muscle cells. Unlike native ghrelin, Hexarelin exhibits greater resistance to enzymatic degradation, allowing sustained activity with a half-life ranging from 55 to 70 minutes. These actions make it a valuable tool in research for exploring growth hormone dynamics and potential therapeutic applications in muscle, bone, and cardiovascular systems.

Structure and Pharmacology

Hexarelin is a synthetic hexapeptide with the amino acid sequence H-His-D-Trp(2-Me)-Ala-Trp-D-Phe-Lys-NH2 (one-letter code: HwAWfK-NH2). Its molecular formula is C47H58N12O6, and it has a molecular weight of 887 g/mol. The peptide features a C-terminal amidation, which enhances its stability against enzymatic degradation. The inclusion of D-amino acids, such as D-tryptophan and D-phenylalanine, along with a methylated tryptophan residue, increases its resistance to breakdown, prolonging its activity compared to natural peptides. This structural design allows Hexarelin to effectively interact with specific receptors in the body, supporting its role as a growth hormone secretagogue.

Pharmacologically, Hexarelin acts primarily as a potent agonist of the ghrelin receptor (GHS-R1a), located in the pituitary gland and hypothalamus. By binding these receptors, it stimulates the release of growth hormone in a dose-dependent manner, which in turn promotes the production of insulin-like growth factor-1 (IGF-1), aiding tissue growth and repair. The peptide also modestly increases prolactin and cortisol levels, influencing metabolic and stress-related pathways. Its effects extend to cardiac tissue, where activation of ghrelin receptors may enhance contractility and protect against apoptosis, suggesting potential benefits for cardiovascular function.

Hexarelin’s resistance to enzymatic degradation results in a half-life ranging from 55 to 70 minutes, allowing sustained activity following subcutaneous or intramuscular injection. Typically used in research settings, its pharmacokinetic profile supports short-term dosing regimens to explore applications in muscle growth, bone density improvement, and cardiac health, though clinical use remains limited due to regulatory restrictions in many regions.

Hexarelin Dosage

Hexarelin is administered through subcutaneous or intramuscular injection to study its growth hormone-releasing effects. Typical doses in experimental protocols range from 1 to 2 micrograms (mcg) per kilogram of body weight, given one to three times daily. For an average adult, this translates to approximately 70 to 300 mcg per subcutaneous (SC) injection, depending on body weight and research objectives. Treatment cycles often span 7 to 14 days, with breaks of similar duration to prevent receptor desensitization.

Researchers dissolve the lyophilized peptide in sterile water or saline before administration to ensure proper delivery. Dosing regimens vary based on the specific goals of the study, such as investigating muscle growth, tissue repair, or cardiac function, and require careful monitoring to assess physiological responses. Clinical use remains limited due to regulatory restrictions in many regions.

Warnings and Cautions

Hexarelin requires careful administration due to potential risks associated with its growth hormone-releasing effects. Those with known hypersensitivity to Hexarelin or its components should avoid its use, as allergic reactions, such as rash or swelling, may occur and necessitate immediate medical attention. Patients with pre-existing conditions like pituitary tumors or adrenal disorders need close monitoring, as Hexarelin’s stimulation of growth hormone, prolactin, and cortisol may exacerbate these conditions. Pregnant or breastfeeding women should avoid using Hexarelin, as safety data in these populations are limited.

Prolonged or excessive dosing may lead to receptor desensitization, reducing the peptide’s effectiveness. Common side effects include injection site irritation, fatigue, or headaches, and persistent symptoms warrant medical evaluation. Hexarelin’s use is restricted in many regions due to limited clinical approval, and administration should occur under strict medical or research supervision to ensure safety.

Research & Clinical Trials

Growth Hormone in Long-Term Hexarelin Therapy

The study found that 16 weeks of twice-daily Hexarelin treatment led to a gradual weakening of the body’s growth hormone (GH) response to Hexarelin, but this effect was reversible once therapy was stopped. During treatment, GH levels in response to Hexarelin were significantly reduced, yet they returned to baseline within four weeks after discontinuation. Levels of insulin-like growth factor I (IGF-I) and IGF binding protein-3 remained unchanged throughout the study, and most markers of bone metabolism, body composition, and bone density were unaffected. The only notable exception was a modest rise in a bone formation marker (C-terminal propeptide of type I collagen) at week 16. Overall, the results suggest that while chronic Hexarelin use can temporarily blunt the GH response, its overall impact on the GH–IGF-I system and other biological measures appears minimal, indicating that its long-term therapeutic potential requires further evaluation. [1]

The Cardiovascular Action of Hexarelin

This study concluded that Hexarelin shows strong, GH-independent protective effects on the cardiovascular system, making it a more stable and potent therapeutic candidate than ghrelin. Evidence from both human and animal studies demonstrated that Hexarelin can improve heart function, increase cardiac output, enhance left ventricular ejection fraction, and reduce cardiac fibrosis, apoptosis, and ischemia-reperfusion injury. It also showed anti-atherosclerotic activity and the ability to counteract myocardial infarction–induced damage. Importantly, these benefits appear to be mediated not only through the growth hormone secretagogue receptor (GHSR 1a) but also through the cardiac-specific CD36 receptor, which explains its superior cardioprotective potency compared with ghrelin. Overall, the findings suggest that Hexarelin could be a promising therapeutic agent for cardiovascular diseases. [2]

Hexarelin & Growth Hormone-Releasing Activity in Humans

This study concluded that Hexarelin is a potent stimulator of growth hormone (GH) release in healthy men in a clear, dose-dependent manner. Single intravenous doses of Hexarelin rapidly increased plasma GH levels, peaking around 30 minutes and returning to baseline within four hours, with a half-life of about 55 minutes. The GH response rose proportionally with higher doses, and the 2 µg/kg dose produced effects close to the estimated maximum response. Overall, the findings confirmed that Hexarelin is an effective and predictable GH-releasing peptide in humans. [3]